Phase II trial of Fingolimod, a sphingosine‐1‐phosphate receptor modulator, in advanced NSCLC and SCLC.

This single-institution, open-label study evaluates daily oral fingolimod 0.5 mg in patients with advanced NSCLC or SCLC who have progressed on chemo-immunotherapy. A six-patient safety lead-in precedes expansion cohorts assessing efficacy separately for NSCLC and SCLC. The trial is sponsored by the Medical University of South Carolina.